{"id":28183,"date":"2024-05-31T15:43:19","date_gmt":"2024-05-31T10:13:19","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=28183"},"modified":"2024-09-23T17:03:42","modified_gmt":"2024-09-23T11:33:42","slug":"key-developments-in-pd-l1-inhibitors","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors","title":{"rendered":"The Journey of PD-(L)1 Inhibitors: Milestones and Breakthroughs"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d01ef8493c6\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d01ef8493c6\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors\/#Approved_PD-L1_Inhibitors_Available_in_the_US_Market\" >Approved PD-(L)1 Inhibitors Available in the US Market<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors\/#KEYTRUDA_Merck\" >KEYTRUDA: Merck<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors\/#OPDIVO_Bristol-Myers_SquibbOno_Pharmaceutical\" >OPDIVO: Bristol-Myers Squibb\/Ono Pharmaceutical<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors\/#TECENTRIQ_GenentechHoffmann-La_Roche\" >TECENTRIQ: Genentech\/Hoffmann-La Roche<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors\/#BAVENCIO_Merck\" >BAVENCIO: Merck<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors\/#IMFINZI_AstraZeneca\" >IMFINZI: AstraZeneca<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors\/#LIBTAYO_RegeneronSanofi\" >LIBTAYO: Regeneron\/Sanofi<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors\/#Other_PD-L1_Inhibitors_in_the_US\" >Other PD-(L)1 Inhibitors in the US<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors\/#Future_Landscape_of_PD-L1_Inhibitors\" >Future Landscape of PD-(L)1 Inhibitors&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>The advent of PD-(L)1 inhibitors marks a monumental shift in the landscape of cancer treatment. These agents have redefined the therapeutic approach to several malignancies, offering hope where traditional therapies often fell short. PD-(L)1 inhibitors are a class of drugs that block the interaction between the programmed death-1 (PD-1) receptor on T cells and its ligand, PD-L1, on tumor cells. This interaction typically acts as a brake on the immune system, preventing T cells from attacking cancer cells. By inhibiting this pathway, PD-(L)1 inhibitors unleash the immune system to recognize and destroy cancer cells.<\/p>\n\n\n\n<p>PD-1 inhibitors are expected to be the leading drug class in terms of sales in the future. Immuno-oncology agents, especially the PD-(L)1 class, have transformed cancer treatment across various tumor types and stages, from metastatic to early stage. The adoption of <a href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management\">PD-(L)1 therapies<\/a> has been driven by their proven versatility. They can be used as monotherapy or in combination with targeted agents like tyrosine kinase inhibitors, chemotherapy, or other immunotherapy agents. This versatility has led to durable tumor responses and improved survival benefits, all while maintaining acceptable toxicity profiles. The improved safety profile of PD-(L)1 therapies compared to chemotherapy allows them to be used as a backbone therapy in a wide range of combination regimens.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-approved-pd-l-1-inhibitors-available-in-the-us-market\"><span class=\"ez-toc-section\" id=\"Approved_PD-L1_Inhibitors_Available_in_the_US_Market\"><\/span><strong>Approved PD-(L)1 Inhibitors Available in the US Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Chemotherapy is the only option for cancer patients before checkpoint inhibitors, but chemotherapy has many side effects. The most explored and successful checkpoint inhibitor is PD-(L)1. As of now <strong>seven PD-1 and three PD-L1<\/strong> approved in the United States.&nbsp;<\/p>\n\n\n\n<p>These inhibitors have revolutionized the treatment landscape for various malignancies, including melanoma, non-small cell lung cancer, renal cell carcinoma, and urothelial carcinoma. Their approval has marked significant progress in immunotherapy, offering new hope to patients with advanced or metastatic cancers by improving survival rates and, in some cases, providing durable responses.<\/p>\n\n\n\n<p><span id=\"docs-internal-guid-7c16c04e-7fff-4e49-fa00-5e76a65a880d\"><\/span><\/p>\n<div dir=\"ltr\" style=\"margin-left: 0pt;\" align=\"left\">\n<table style=\"border: none; border-collapse: collapse;\"><colgroup><col width=\"75\" \/><col width=\"97\" \/><col width=\"87\" \/><col width=\"110\" \/><col width=\"84\" \/><col width=\"74\" \/><col width=\"128\" \/><\/colgroup>\n<tbody>\n<tr style=\"height: 27pt;\">\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\" colspan=\"7\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: center; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">List of Approved PD-1\/PD-L1 Inhibitors<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 42pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Drug Category<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Generic Name<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Brand Name<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Manufacturer<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">First Approval Date in the US<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">US Patent Expiry<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">2023 Sales (WW)<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">(in USD million)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 29.25pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">PD-1 inhibitor<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Pembrolizumab<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">KEYTRUDA<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Merck<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">09\/04\/2014<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">2028<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">25,011<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 58.5pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">PD-1 inhibitor<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Nivolumab<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">OPDIVO<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Ono Pharmaceutica and Bristol Myers Squibb<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">12\/22\/2014<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">2028<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">9,009<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 38.25pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">PD-L1 inhibitor<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Atezolizumab<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">TECENTRIQ<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Genentech<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">05\/18\/2016<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">2028 (IV) 2032 (SC)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">4,194<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 38.25pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">PD-L1 inhibitor<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Avelumab<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">BAVENCIO<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Merck KGaA<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">03\/23\/2017<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">2034<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">772<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 38.25pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">PD-L1 inhibitor<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Durvalumab<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">IMFINZI<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">AstraZeneca<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">05\/01\/2017<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">2031<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">4,237<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 29.25pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">PD-1 inhibitor<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Cemiplimab<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">LIBTAYO<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Regeneron<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">09\/28\/2018<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">2038<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">863<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 29.25pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">PD-1 inhibitor<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Dostarlimab<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">JEMPERLI<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">GSK<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">04\/22\/2021<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">2034<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">141<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 29.25pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">PD-1 inhibitor<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Retifanlimab<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">ZYNYZ<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Incyte<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">03\/22\/2023<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">2036<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">1<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 58.5pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">PD-1 inhibitor<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Toripalimab<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">LOQTORZI<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Shanghai Junshi Biosciences and Coherus BioSciences<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">10\/29\/2023<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">2030 (ODE exclusivity)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">0.6<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 29.25pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">PD-1 inhibitor<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Tislelizumab<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">TEVIMBRA<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">BeiGene<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">03\/14\/2024<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">2033<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 1pt 5pt 0pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.9999974999999999pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 12pt; margin-bottom: 12pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211;<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>As per DelveInsight analysis, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/pd-L1-inhibitors-market\">market size of PD-(L)1 inhibitors<\/a> in the US was nearly <strong>USD 26 billion<\/strong> in 2023. The leader of the PD-(L)1 market has been <strong>KEYTRUDA <\/strong>for a long time, and it is expected to dominate in the future. The major sales share of KEYTRUDA is coming from NSCLC, TNBC, and melanoma.<\/p>\n\n\n\n<p>The in-depth assessment of FDA-approved PD-(L)1 inhibitors along with their detailed approval timeline is given below:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-keytruda-merck\"><span class=\"ez-toc-section\" id=\"KEYTRUDA_Merck\"><\/span><strong>KEYTRUDA: Merck<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>KEYTRUDA <\/strong>is a PD-1-blocking antibody. It is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-(L)1 and PD-(L)2, thereby activating T lymphocytes, which may affect both tumor cells and healthy cells. In some cancers, it is only given to patients whose tumors produce high protein levels known as PD-(L)1. It is approved for multiple types of cancer. It was first approved by the FDA in September 2014 for <a href=\"https:\/\/www.delveinsight.com\/report-store\/pd-1-refractory-advanced-melanoma-market\">advanced melanoma<\/a>. Since then, it has received multiple approvals, and the latest FDA approval was in January 2024 as a treatment for patients with FIGO 2014 Stage III-IVA cervical cancer. In February 2024, Merck announced that the FDA has accepted for priority review a new sBLA seeking approval for KEYTRUDA in combination with standard-of-care chemotherapy (carboplatin and paclitaxel), followed by KEYTRUDA as a single agent for the treatment of patients with primary advanced or recurrent endometrial carcinoma. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of <strong>June 21, 2024<\/strong>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"438\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153935\/Approval-Timeline-of-KEYTRUDA-in-the-US-1024x438.png\" alt=\"Approval Timeline of KEYTRUDA in the US\" class=\"wp-image-28191\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153935\/Approval-Timeline-of-KEYTRUDA-in-the-US-1024x438.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153935\/Approval-Timeline-of-KEYTRUDA-in-the-US-300x128.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153935\/Approval-Timeline-of-KEYTRUDA-in-the-US-150x64.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153935\/Approval-Timeline-of-KEYTRUDA-in-the-US-768x329.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153935\/Approval-Timeline-of-KEYTRUDA-in-the-US-1536x658.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153935\/Approval-Timeline-of-KEYTRUDA-in-the-US-2048x877.png 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153935\/Approval-Timeline-of-KEYTRUDA-in-the-US-1568x671.png 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-opdivo-bristol-myers-squibb-ono-pharmaceutical\"><span class=\"ez-toc-section\" id=\"OPDIVO_Bristol-Myers_SquibbOno_Pharmaceutical\"><\/span><strong>OPDIVO: Bristol-Myers Squibb\/Ono Pharmaceutical<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>OPDIVO (nivolumab)<\/strong> is a PD-1 inhibitor. It first received the US FDA accelerated approval in December 2014 for unresectable or metastatic melanoma. Currently, OPDIVO as monotherapy is undergoing Phase III investigation for adjuvant hepatocellular carcinoma, peri-adjuvant muscle-invasive urothelial carcinoma, and adjuvant NSCLC Stages IB-IIIA. In addition, the drug is currently in the registrational phase for peri-adjuvant NSCLC (in the US and EU).<\/p>\n\n\n\n<p>OPDIVO also approved in NSCLC, generated around <strong>USD 1.2 billion<\/strong> sales in the US which is less than KEYTRUDA. But in Melanoma, OPDIVO is the leader in the US. KEYTRUDA and OPDIVO captured around <strong>80%<\/strong> of PD-(L)1 market in 2023. KEYTRUDA is a leader in the <strong>US and EU markets<\/strong>, whereas OPDIVO is leading in <strong>Japan market<\/strong>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"508\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153959\/Approval-Timeline-of-OPDIVO-in-the-US-1024x508.png\" alt=\"Approval Timeline of OPDIVO in the US\" class=\"wp-image-28192\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153959\/Approval-Timeline-of-OPDIVO-in-the-US-1024x508.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153959\/Approval-Timeline-of-OPDIVO-in-the-US-300x149.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153959\/Approval-Timeline-of-OPDIVO-in-the-US-150x74.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153959\/Approval-Timeline-of-OPDIVO-in-the-US-768x381.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153959\/Approval-Timeline-of-OPDIVO-in-the-US-1536x762.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153959\/Approval-Timeline-of-OPDIVO-in-the-US-2048x1016.png 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153959\/Approval-Timeline-of-OPDIVO-in-the-US-1568x778.png 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-tecentriq-genentech-hoffmann-la-roche\"><span class=\"ez-toc-section\" id=\"TECENTRIQ_GenentechHoffmann-La_Roche\"><\/span><strong>TECENTRIQ: Genentech\/Hoffmann-La Roche<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>TECENTRIQ <\/strong>is a cancer <a href=\"https:\/\/www.delveinsight.com\/report-store\/immune-checkpoint-inhibitors-market\">immune checkpoint inhibitor<\/a> targeting PD-L1, which is a protein expressed on tumor and tumor-infiltrating immune cells. It is an Fc-engineered, humanized, non-glycosylated IgG1 kappa immunoglobulin with a calculated molecular mass of 145 kDa. PD-L1 blocks T-cell activity by binding with PD-1 and B7.1 receptors on T-cell surface. By inhibiting PD-L1, TECENTRIQ may enable the activation of T cells and boost the immune response against cancer cells. TECENTRIQ holds the leading position in small-cell lung cancer.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"323\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/17175543\/Approval-Timeline-of-KEYTRUDA-in-the-US-1024x323.jpg\" alt=\"Approval Timeline of KEYTRUDA in the US\" class=\"wp-image-28346\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/17175543\/Approval-Timeline-of-KEYTRUDA-in-the-US-1024x323.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/17175543\/Approval-Timeline-of-KEYTRUDA-in-the-US-300x95.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/17175543\/Approval-Timeline-of-KEYTRUDA-in-the-US-150x47.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/17175543\/Approval-Timeline-of-KEYTRUDA-in-the-US-768x243.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/17175543\/Approval-Timeline-of-KEYTRUDA-in-the-US-1536x485.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/17175543\/Approval-Timeline-of-KEYTRUDA-in-the-US-2048x647.jpg 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/17175543\/Approval-Timeline-of-KEYTRUDA-in-the-US-1568x495.jpg 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>In March 2024, <strong>Chugai Pharmaceutical<\/strong> filed a regulatory application with the MHLW for TECENTRIQ IV infusion 1,200 mg for an additional indication of alveolar soft part sarcoma. The company is expecting Phase III (SKYSCRAPER-01) tiragolumab + TECENTRIQ in 1L PD-L1+ NSCLC final OS results in the <strong>second half of 2024<\/strong>.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-bavencio-merck\"><span class=\"ez-toc-section\" id=\"BAVENCIO_Merck\"><\/span><strong>BAVENCIO: Merck<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>BAVENCIO (avelumab)<\/strong> is a human anti-programmed death ligand-1 (PD-L1) antibody. BAVENCIO has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors, BAVENCIO has been shown to suppress the T-cell-mediated antitumor immune response in preclinical models. It has also been shown to induce NK cell-mediated direct tumor cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. In November 2014, Merck and Pfizer announced a strategic alliance to codevelop and co-commercialize BAVENCIO.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"201\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/17180652\/Approval-Timeline-of-BAVENCIO-in-the-US-1024x201.jpg\" alt=\"Approval Timeline of BAVENCIO in the US\" class=\"wp-image-28352\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/17180652\/Approval-Timeline-of-BAVENCIO-in-the-US-1024x201.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/17180652\/Approval-Timeline-of-BAVENCIO-in-the-US-300x59.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/17180652\/Approval-Timeline-of-BAVENCIO-in-the-US-150x29.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/17180652\/Approval-Timeline-of-BAVENCIO-in-the-US-768x151.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/17180652\/Approval-Timeline-of-BAVENCIO-in-the-US-1536x301.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/17180652\/Approval-Timeline-of-BAVENCIO-in-the-US-1568x308.jpg 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/17180652\/Approval-Timeline-of-BAVENCIO-in-the-US.jpg 1805w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>In addition, avelumab is under clinical investigation for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\">treatment of NSCLC<\/a>, solid tumors, metastatic urothelial cancer, metastatic urothelial cancer, and other indications. In March 2023, Merck strengthened its oncology franchise by regaining exclusive worldwide rights to develop, manufacture, and commercialize BAVENCIO following the termination of their Alliance agreement with Pfizer.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-imfinzi-astrazeneca\"><span class=\"ez-toc-section\" id=\"IMFINZI_AstraZeneca\"><\/span><strong>IMFINZI: AstraZeneca<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>IMFINZI <\/strong>is a human monoclonal antibody that binds to PD-(L)1 and blocks the interaction of PD-L1 with PD 1 and CD80, countering the tumor\u2019s immune-evading tactics and releasing the inhibition of immune responses. It is approved in four indications, NSCLC, ES-SCLC, BTC, and HCC. The first FDA approval of IMFINZI was in February 2018 for patients with Stage III NSCLC.&nbsp;<\/p>\n\n\n\n<p>IMFINZI + IMJUDO combination was approved remarkably after 11 and a half years in the US approvals of the first CLTA4 for NSCLC, liver cancer, and BTC that gives another option to patients from OPDIVO + YERVOY. In 2023, IMFINZI\u2019s overall sales reached approximately <strong>USD 4 billion <\/strong>worldwide, with the majority of revenue generated from the NSCLC indication.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"389\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154113\/Approval-timeline-of-IMFINZI-in-the-US-1024x389.png\" alt=\"Approval timeline of IMFINZI in the US\" class=\"wp-image-28195\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154113\/Approval-timeline-of-IMFINZI-in-the-US-1024x389.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154113\/Approval-timeline-of-IMFINZI-in-the-US-300x114.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154113\/Approval-timeline-of-IMFINZI-in-the-US-150x57.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154113\/Approval-timeline-of-IMFINZI-in-the-US-768x292.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154113\/Approval-timeline-of-IMFINZI-in-the-US-1536x583.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154113\/Approval-timeline-of-IMFINZI-in-the-US-1568x595.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154113\/Approval-timeline-of-IMFINZI-in-the-US.png 2010w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>The company is expecting an FDA decision for IMFINZI as neoadjuvant therapy in the <strong>AEGEAN trial<\/strong> in the first half of 2024 for small-cell lung cancer, and the company is anticipating Phase III data readout of the NILE trial in first-line bladder cancer in the second half of 2024.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-libtayo-regeneron-sanofi\"><span class=\"ez-toc-section\" id=\"LIBTAYO_RegeneronSanofi\"><\/span><strong>LIBTAYO: Regeneron\/Sanofi<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>LIBTAYO <\/strong>binds to PD-1 to help immune cells kill cancer cells better and is used to treat different types of cancer. LIBTAYO is used to treat certain types of basal cell carcinoma and cutaneous squamous cell carcinoma that are locally advanced or have spread to other parts of the body. It is also used alone or with other drugs to treat <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\">adults with non-small cell lung cancer<\/a> that is locally advanced or has spread to other parts of the body and may have the PD-L1 protein but does not have a mutation in the EGFR, ALK, or ROS1 gene. It is also being studied in the treatment of other types of cancer. LIBTAYO blocks PD-1 and helps the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor.<\/p>\n\n\n\n<p>The company is planning to conduct a pivotal interim analysis from the Phase III study in adjuvant CSCC in the second half of 2024. The company is planning to report potentially pivotal initial results from the Phase II\/III study of fianlimab (LAG-3 antibody) in combination with LIBTAYO in first-line metastatic melanoma and initial combination data in first-line advanced NSCLC in the second half of 2024.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"501\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154137\/Approval-Timeline-of-LIBTAYO-in-the-US-1024x501.png\" alt=\"Approval Timeline of LIBTAYO in the US\" class=\"wp-image-28196\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154137\/Approval-Timeline-of-LIBTAYO-in-the-US-1024x501.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154137\/Approval-Timeline-of-LIBTAYO-in-the-US-300x147.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154137\/Approval-Timeline-of-LIBTAYO-in-the-US-150x73.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154137\/Approval-Timeline-of-LIBTAYO-in-the-US-768x376.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154137\/Approval-Timeline-of-LIBTAYO-in-the-US-1536x751.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154137\/Approval-Timeline-of-LIBTAYO-in-the-US-1568x767.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154137\/Approval-Timeline-of-LIBTAYO-in-the-US.png 1701w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>LIBTAYO is the market leader for non-melanoma skin cancers, such as cutaneous squamous cell carcinoma and basal cell carcinoma, and is expected to maintain its dominance in the coming years.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-other-pd-l-1-inhibitors-in-the-us\"><span class=\"ez-toc-section\" id=\"Other_PD-L1_Inhibitors_in_the_US\"><\/span><strong>Other PD-(L)1 Inhibitors in the US<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Following the approvals of BAVENCIO and KEYTRUDA for Merkel cell carcinoma, <strong>ZYNYZ <\/strong>also received approval for this indication. With a Merkel cell carcinoma patient population of approximately <strong>3,000<\/strong> cases in the US, ZYNYZ is expected to encounter strong competition from these established drugs, and it is projected that ZYNYZ could achieve near to <strong>USD 50 million<\/strong> in sales by 2034.<\/p>\n\n\n\n<p>The PD-(L)1 segment in China has been growing rapidly, and several businesses are attempting to market their products in developed nations and other foreign markets. <strong>TEVIMBRA and LOQTORZI<\/strong> are both approved in the US and developed by Chinese companies. TEVIMBRA was first approved in Europe based on trial data from China and later received US approval for esophageal cancer. Recently, TEVIMBRA also gained approval in Europe for NSCLC.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"505\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154156\/Approval-Timeline-of-Other-PD-L1-Inhibitors-in-the-US-1024x505.png\" alt=\"Approval Timeline of Other PD-(L)1 Inhibitors in the US\" class=\"wp-image-28197\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154156\/Approval-Timeline-of-Other-PD-L1-Inhibitors-in-the-US-1024x505.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154156\/Approval-Timeline-of-Other-PD-L1-Inhibitors-in-the-US-300x148.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154156\/Approval-Timeline-of-Other-PD-L1-Inhibitors-in-the-US-150x74.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154156\/Approval-Timeline-of-Other-PD-L1-Inhibitors-in-the-US-768x379.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154156\/Approval-Timeline-of-Other-PD-L1-Inhibitors-in-the-US-1536x758.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154156\/Approval-Timeline-of-Other-PD-L1-Inhibitors-in-the-US-1568x774.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31154156\/Approval-Timeline-of-Other-PD-L1-Inhibitors-in-the-US.png 1682w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>After a 2-year delay, <a href=\"https:\/\/www.delveinsight.com\/blog\/loqtorzi-for-nasopharyngeal-carcinoma-treatment\"><strong>LOQTORZI<\/strong><\/a>, approved in the US for nasopharyngeal carcinoma, is the first PD-1 inhibitor approved in this sub-segment. It is the first PD-1 inhibitor to be approved by the FDA based on data from trials conducted in China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-future-landscape-of-pd-l-1-inhibitors-nbsp\"><span class=\"ez-toc-section\" id=\"Future_Landscape_of_PD-L1_Inhibitors\"><\/span><strong>Future Landscape of PD-(L)1 Inhibitors&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>KEYTRUDA<\/strong>, developed by <strong>Merck<\/strong>, has indeed emerged as a dominant force in the field of <a href=\"https:\/\/www.delveinsight.com\/report-store\/oncology-drugs-market\">oncology drugs<\/a>, particularly in the realm of immunotherapy. Its success can be attributed to various factors, including Merck\u2019s effective commercial tactics, extensive clinical research, and strategic collaborations. Merck\u2019s commercial strategy for KEYTRUDA has been multifaceted. In terms of R&amp;D, Merck has demonstrated a commitment to exploring KEYTRUDA\u2019s potential in combination with other drugs to enhance its effectiveness and expand its utility across different cancer types. Vibostolimab, quavonlimab, and faveselimab\u2014are examples of agents being evaluated in combination with KEYTRUDA in clinical trials.<\/p>\n\n\n\n<p>These combination therapies aim to leverage synergistic effects, targeting multiple pathways involved in cancer progression and immune evasion. By evaluating KEYTRUDA in combination with other novel agents, Merck\u2019s R&amp;D department seeks to improve treatment outcomes for cancer patients further and maintain the drug\u2019s competitive edge in the rapidly evolving oncology landscape.<\/p>\n\n\n\n<p>KEYTRUDA\u2019s and OPDIVO (IV) patent is set to expire in the US in <strong>2028<\/strong>. This expiration is expected to significantly affect the <a href=\"https:\/\/www.delveinsight.com\/report-store\/pd-L1-inhibitors-market\">PD-(L)1 market<\/a>, as KEYTRUDA and OPDIVO currently hold substantial market shares. The loss of two leading medications\u2019 patent exclusivity will have a significant effect on the PD-(L)1 market. While several novel PD-1\/PD-L1 inhibitors are being studied for various cancer types, such as spartalizumab, sasanlimab, zimberelimab, sugemalimab, HLX10, INCB99280, and balstilimab, they are not expected to significantly reduce the impact of KEYTRUDA and OPDIVO on the PD-(L)-1 market. To tackle the biosimilar impact, Bristol Myers Squibb has already developed the subcutaneous formulation of OPDIVO, and the patent expires for SC formulation in 2030.<\/p>\n\n\n\n<p>Success in the competitive field of PD-1\/PD-L1 hinges on standing out from the crowd. Companies must make an effort to be creative and target areas where current treatments are not ideal. Coming out on top in novel measures or addressing a gap can also differentiate businesses in this cutthroat climate.&nbsp;<\/p>\n\n\n\n<p>GSK\u2019s decision to focus on head and neck cancer for JEMPERLI\u2019S next major opportunity in a front-line setting shows courage. <a href=\"https:\/\/www.delveinsight.com\/report-store\/pd-L1-inhibitors-market\">PD-(L)1 drugs<\/a> have faced difficulty in treating this cancer. OPDIVO, IMFINZI, and BAVENCIO did not succeed in eight important Phase III trials for head and neck cancer, but examining Jade\u2019s design gives some hope.<\/p>\n\n\n\n<p>Chinese companies are increasingly targeting the US market, buoyed by the recent approvals of <strong>TEVIMBRA and LOQTORZI<\/strong>. Companies such as <strong>Alphamab Oncology, Shanghai Henlius Biotech, and CStone Pharmaceuticals<\/strong> are developing drugs for the US market to capture significant revenue and provide patients with lower-cost options. For instance, Coherus has priced LOQTORZI <strong>20%<\/strong> lower than KEYTRUDA. These developments are likely to be closely watched by the medical community, patients, and insurance providers, given the substantial medical demand.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/pd-L1-inhibitors-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/23170252\/PD-L1-Inhibitors-Market-Outlook--1024x194.jpg\" alt=\"PD-(L)1 Inhibitors Market Outlook \" class=\"wp-image-29701\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/23170252\/PD-L1-Inhibitors-Market-Outlook--1024x194.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/23170252\/PD-L1-Inhibitors-Market-Outlook--300x57.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/23170252\/PD-L1-Inhibitors-Market-Outlook--150x28.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/23170252\/PD-L1-Inhibitors-Market-Outlook--768x145.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/23170252\/PD-L1-Inhibitors-Market-Outlook--1536x291.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/23170252\/PD-L1-Inhibitors-Market-Outlook-.jpg 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>The advent of PD-(L)1 inhibitors marks a monumental shift in the landscape of cancer treatment. These agents have redefined the therapeutic approach to several malignancies, offering hope where traditional therapies often fell short. PD-(L)1 inhibitors are a class of drugs that block the interaction between the programmed death-1 (PD-1) receptor on T cells and its [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":28187,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[17941,17967,345,16912,21416,431,22125,22126,454,456,3069,457,1716,2792],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-28183","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-bavencio","tag-imfinzi","tag-keytruda","tag-libtayo","tag-loqtorzi","tag-opdivo","tag-pd-l1-inhibitors","tag-pd-l1-market","tag-pd-1-and-pd-l-1-inhibitors","tag-pd-1-and-pd-l1-inhibitors","tag-pd-1-inhibitor","tag-pd-1pdl-1","tag-pd-l1","tag-tecentriq","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Key Developments in PD-(L)1 Inhibitors<\/title>\n<meta name=\"description\" content=\"Advent of PD-(L)1 inhibitors marks a monumental shift in landscape of cancer treatment. They are expected to be leading drug class in future\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Key Developments in PD-(L)1 Inhibitors\" \/>\n<meta property=\"og:description\" content=\"Advent of PD-(L)1 inhibitors marks a monumental shift in landscape of cancer treatment. They are expected to be leading drug class in future\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-31T10:13:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T11:33:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153735\/key-developments-in-pd-l1-inhibitors.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Key Developments in PD-(L)1 Inhibitors","description":"Advent of PD-(L)1 inhibitors marks a monumental shift in landscape of cancer treatment. They are expected to be leading drug class in future","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors","og_locale":"en_US","og_type":"article","og_title":"Key Developments in PD-(L)1 Inhibitors","og_description":"Advent of PD-(L)1 inhibitors marks a monumental shift in landscape of cancer treatment. They are expected to be leading drug class in future","og_url":"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-05-31T10:13:19+00:00","article_modified_time":"2024-09-23T11:33:42+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153735\/key-developments-in-pd-l1-inhibitors.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors","url":"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors","name":"Key Developments in PD-(L)1 Inhibitors","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153735\/key-developments-in-pd-l1-inhibitors.png","datePublished":"2024-05-31T10:13:19+00:00","dateModified":"2024-09-23T11:33:42+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Advent of PD-(L)1 inhibitors marks a monumental shift in landscape of cancer treatment. They are expected to be leading drug class in future","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/key-developments-in-pd-l1-inhibitors#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153735\/key-developments-in-pd-l1-inhibitors.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153735\/key-developments-in-pd-l1-inhibitors.png","width":466,"height":284,"caption":"key-developments-in-pd-l1-inhibitors"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/31153735\/key-developments-in-pd-l1-inhibitors-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Bavencio<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Imfinzi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Keytruda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Libtayo<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Loqtorzi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Opdivo<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-(L)1 Inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-(L)1 market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1 and PD-L 1 inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1 and PD-L1 inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1 inhibitor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1\/PDL-1<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-L1<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Tecentriq<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Bavencio<\/span>","<span class=\"advgb-post-tax-term\">Imfinzi<\/span>","<span class=\"advgb-post-tax-term\">Keytruda<\/span>","<span class=\"advgb-post-tax-term\">Libtayo<\/span>","<span class=\"advgb-post-tax-term\">Loqtorzi<\/span>","<span class=\"advgb-post-tax-term\">Opdivo<\/span>","<span class=\"advgb-post-tax-term\">PD-(L)1 Inhibitors<\/span>","<span class=\"advgb-post-tax-term\">PD-(L)1 market<\/span>","<span class=\"advgb-post-tax-term\">PD-1 and PD-L 1 inhibitors<\/span>","<span class=\"advgb-post-tax-term\">PD-1 and PD-L1 inhibitors<\/span>","<span class=\"advgb-post-tax-term\">PD-1 inhibitor<\/span>","<span class=\"advgb-post-tax-term\">PD-1\/PDL-1<\/span>","<span class=\"advgb-post-tax-term\">PD-L1<\/span>","<span class=\"advgb-post-tax-term\">Tecentriq<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on May 31, 2024","modified":"Updated on Sep 23, 2024"},"absolute_dates_time":{"created":"Posted on May 31, 2024 3:43 pm","modified":"Updated on Sep 23, 2024 5:03 pm"},"featured_img_caption":"key-developments-in-pd-l1-inhibitors","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28183","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=28183"}],"version-history":[{"count":10,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28183\/revisions"}],"predecessor-version":[{"id":29703,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28183\/revisions\/29703"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/28187"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=28183"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=28183"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=28183"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=28183"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=28183"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}